1. Mazdak H, Tolou GZ, Gholumpour M. Investigation of bladder cancer incidence in Isfahan, Iran. Tehran Univ. Med. J. 2019;77(4):252-6.

2. Goonewardene SS, Persad R, Motiwala H, Albala D. Systematic Review Results on Bladder Cancer Epidemiology, Occupational Hazards and Risk Factors. Management of Non-Muscle Invasive Bladder Cancer. 2020:53-61.

3. Jahrreiss V, Pradere B, Laukhtina E, Mori K, Shariat SF. Catalog of exogenous risk factors for bladder carcinogenesis. Curr. Opin. Urol . 2020;30(3):449-56.

4. Li F, Hong X, Hou L, Lin F, Chen P, Pang S, Du Y, Huang H, Tan W. A greater number of dissected lymph nodes is associated with more favorable outcomes in bladder cancer treated by radical cystectomy: a meta-analysis. Oncotarget. 2016;7(38):61284. [DOI:10.18632/oncotarget.11343]

5. DeGEORGE KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. Am Fam Physician. 2017;96(8):507-14.

6. Guallar-Garrido S, Julián E. Bacillus Calmette-Guérin (BCG) therapy for bladder cancer: an update. ImmunoTargets Ther. 2020;9:1. [DOI:10.2147/ITT.S202006]

7. Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed. Pharmacother. 2020;129:110393. [DOI:10.1016/j.biopha.2020.110393]

8. Li P, Chen J, Miyamoto H. Androgen receptor signaling in bladder cancer. Cancers. 2017;9(2):20. [DOI:10.3390/cancers9020020]

9. Mizushima T, Tirador KA, Miyamoto H. Androgen receptor activation: a prospective therapeutic target for bladder cancer? Expert Opin. Ther. Targets. 2017; 21(3):249-57.

10. Luna‐Velez MV, Dijkstra JJ, Heuschkel MA, Smit FP, van de Zande G, Smeets D, Sedelaar JM, Vermeulen M, Verhaegh GW, Schalken JA. Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder. Molecular Oncology. 2021.

11. van Puffelen JH, Keating ST, Oosterwijk E, van der Heijden AG, Netea MG, Joosten LA, Vermeulen SH. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nature Reviews Urology. 2020;17(9):513-25. [DOI:10.1038/s41585-020-0346-4]

12. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BW, Rouprêt M, Shariat SF, Sylvester R, Zigeuner R. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update. European urology. 2019;76(5):639-57. [DOI:10.1016/j.eururo.2019.08.016]

13. Larsen ES, Joensen UN, Poulsen AM, Goletti D, Johansen IS. Bacillus Calmette-Guerin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. Apmis. 2020 Feb;128(2):92-103.

14. Koch GE, Smelser WW, Chang SS. Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How to Manage Them. Urology. 2020.

15. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. The Journal of urology. 2003 Jan;169(1):96-100.

16. Williams SB, Howard LE, Foster ML, Klaassen Z, Sieluk J, De Hoedt AM, Freedland SJ. Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System. JAMA network open. 2021 Mar 1;4(3):e213800-.

17. Juvet, T., Mari, A., Lajkosz, K., Wallis, C.J., Kuk, C., Erlich, A., Krimus, L., Fleshner, N.E., Kulkarni, G.S. and Zlotta, A.R., 2020, November. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. In Urologic Oncology: Seminars and Original Investigations (Vol. 38, No. 11, pp. 850-e9). Elsevier.

18. Zhu D, Srivastava A, Agalliu I, Fram E, Kovac EZ, Aboumohamed A, et al. Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population. The Journal of Urology. 2021 http://doi.org/10.1097/JU.0000000000001694

19. Morales EE, Grill S, Svatek RS, Kaushik D, Thompson Jr IM, Ankerst DP, Liss MA. Finasteride reduces risk of bladder cancer in a large prospective screening study. European urology. 2016; 69(3):407-10. [DOI:10.1016/j.eururo.2006.07.001]

20. Moroz A, Delella FK, Almeida R, Lacorte LM, Favaro WJ, Deffune E, Felisbino SL. Finasteride inhibits human prostate cancer cell invasion through MMP2 and MMP9 downregulation. PLoS One. 2013;8(12):e84757.

21. Mäkelä VJ, Kotsar A, Tammela TL, Murtola TJ. Bladder cancer survival of men receiving 5α-reductase inhibitors. The Journal of urology. 2018;200(4):743-8. [DOI:10.1016/j.juro.2018.04.082]

22. Yong C, Steinberg RL, O'Donnell MA. Severe infectious complications of intravesical Bacillus Calmette-Guérin: a case series of 10 patients. Urology. 2020 137:79-83.

23. Liu L, Zhao S, Li F, Li E, Kang R, Luo L, Luo J, Wan S, Zhao Z. Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. The journal of sexual medicine. 2016;13(9):1297-310. [DOI:10.1016/j.jsxm.2016.07.006]

24. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α‐reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. The journal of sexual medicine. 2011;8(3):872-84. [DOI:10.1111/j.1743-6109.2010.02157.x]

25. Kakehi Y, Hirao Y, Kim WJ, Ozono S, Masumori N, Miyanaga N, Nasu Y, Yokomizo A. Bladder cancer working group report. Japanese journal of clinical oncology. 2010;40(suppl_1):i57-64.

26. Fankhauser CD, Mostafid H. Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle. Current opinion in urology. 2018;28(1):88-92. [DOI:10.1097/MOU.0000000000000452]